- Home
- JHG vs CDTX Comparison
JHG vs CDTX Comparison
Compare JHG & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JHG | CDTX |
|---|---|---|
| Founded | 1934 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | 73 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.9B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | JHG | CDTX |
|---|---|---|
| Price | $45.60 | $220.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $47.88 | ★ $128.75 |
| AVG Volume (30 Days) | 811.3K | ★ 2.3M |
| Earning Date | 01-30-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ 33.81 | N/A |
| EPS | ★ 3.39 | N/A |
| Revenue | ★ $2,663,300,000.00 | N/A |
| Revenue This Year | $10.79 | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $13.42 | ★ N/A |
| Revenue Growth | ★ 14.14 | N/A |
| 52 Week Low | $28.26 | $15.22 |
| 52 Week High | $49.42 | $221.20 |
Technical Indicators
Market Signals| Indicator | JHG | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 85.69 |
| Support Level | $45.22 | $219.60 |
| Resistance Level | $46.36 | $220.78 |
| Average True Range (ATR) | 0.80 | 0.71 |
| MACD | 0.23 | -4.15 |
| Stochastic Oscillator | 76.96 | 41.58 |
Price Performance
Historical ComparisonAbout JHG Janus Henderson Group plc
Janus Henderson Group provides investment management services to retail intermediary (50% of managed assets), self-directed (20%) and institutional (30%) clients. At the end of September 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $484 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (67%), with customers from Europe, the Middle East, Africa, and Latin America (25%) and the Asia-Pacific region (8%) accounting for the remainder.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.